Breast cancer vaccine - AVAX TechnologiesAlternative Names: B-Vax
Latest Information Update: 05 Feb 2008
At a glance
- Originator Thomas Jefferson University
- Developer University of Tokyo
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Breast cancer